Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYes, certain anti-sickness tablets can be taken alongside Mounjaro, and many people find them helpful during the first few weeks of treatment. Nausea is one of the most commonly reported side effects of tirzepatide, particularly after starting or after a dose step-up — and your prescriber can advise on suitable options for you. These are prescription-only medicines, so any decision about managing side effects should be made with your clinical team rather than on your own.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Mounjaro (tirzepatide) activates two gut-hormone receptors (GIP and GLP-1) that slow the rate at which the stomach empties. That slowing is part of how the medicine reduces appetite, but it also means food and fluid sit in the stomach longer than usual, which can trigger nausea, burping or a sensation of fullness after very small amounts. This is a question our prescribers hear most weeks: "is the nausea normal, and will it stop?" The honest answer is yes, for most people, it does ease — typically within a few days to a couple of weeks of each dose change. The pattern of sickness with Mounjaro tends to follow dose increases rather than continuing at a constant level throughout treatment.
Knowing this matters because it shapes whether anti-sickness medication is genuinely needed or whether small dietary changes (eating more slowly, keeping portions modest, staying upright after meals, keeping meals low-fat) are enough to get through the adjustment window. The causes of Mounjaro-related nausea are well understood, and most people do not need to add another medicine to manage them.
If dietary changes are not enough and nausea is making daily life difficult, anti-sickness medicines are worth discussing with your prescriber. Common over-the-counter options in the UK include cyclizine (an antihistamine-based antiemetic) and promethazine. There is no published evidence of a direct pharmacological interaction between these and tirzepatide, but that is not the same as saying they are automatically fine for every individual.
Several things need checking. First, some anti-sickness medicines have their own side-effect profiles (drowsiness, dry mouth, urinary hesitancy) that may combine awkwardly with how you are feeling on tirzepatide. Second, because Mounjaro slows gastric emptying, any oral medicine you take (including an anti-sickness tablet) may be absorbed more slowly or unpredictably than usual. This is the same principle that underpins the guidance on anti-sickness tablets for Mounjaro more broadly. Third, if you take other regular medicines, adding an antiemetic could affect their timing. A pharmacist or your prescriber can review your full medicine list quickly, it is not a complicated conversation, but it is a necessary one.
The NHS patient information for tirzepatide sets out the known side effects and the general advice on managing them; it is worth reading alongside any decision about adding a new medicine.
Most Mounjaro-related nausea is an inconvenience rather than a danger sign. There are, however, symptoms that should not be managed with an anti-sickness tablet and then waited out. The MHRA issued a Drug Safety Update in January 2026 specifically flagging acute pancreatitis as an infrequent but serious risk with GLP-1 medicines: severe stomach pain that does not ease and reaches through to the back, with or without vomiting, warrants urgent medical assessment rather than a dose of cyclizine. Gallbladder symptoms, severe dehydration from repeated vomiting, and significant dizziness also need prompt attention. You can read more about the full side-effect profile of Mounjaro to understand where the usual adjustment symptoms end and where concern begins. The Yellow Card scheme at yellowcard.mhra.gov.uk allows you to report any suspected side effect, and doing so genuinely helps regulators build a clearer safety picture.
If you are in doubt about any symptom, contact your prescriber or call NHS 111. Do not try to push through on an anti-sickness tablet alone when something feels wrong.
If nausea after a dose increase is significant, the most important conversation is with whoever is overseeing your treatment. In some cases, staying at the current dose for an extra four weeks rather than titrating upward is the right call, the goal is the highest dose you tolerate well, not the highest dose on paper. Mounjaro's licensed titration schedule is designed with exactly this flexibility. You can explore what appropriate anti-sickness support for Mounjaro looks like in practice, including non-medicine approaches.
For anyone starting out or reconsidering their options, Mounjaro's clinical profile and how it works is explained in detail on our treatment page, and the cost of private Mounjaro treatment is covered separately if that is on your mind. Treatment through nume, sorry, through nume always includes 7-day aftercare access so you can raise exactly these questions without waiting for a GP appointment. If nausea is affecting your quality of life, check your eligibility and speak to our prescribers as part of your consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.